Retrieve available abstracts of 62 articles: HTML format
Single Articles
September 2025
BRITO-ROCHA T, Constancio V, Leite-Silva P, Carvalho-Maia C, et al Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood
test.
Int J Cancer. 2025;157:1006-1019. PubMedAbstract available
SUN Y, Deng Z, Sun H, Wei X, et al Prognostic impact of the timing of immunotherapy in first-line immunochemotherapy
for patients with advanced lung adenocarcinoma: A propensity score-matched
analysis.
Int J Cancer. 2025;157:916-926. PubMedAbstract available
KANNO C, Kojima M, Watanabe Y, Honda R, et al Molecular targeted drugs affect the development of antiresorptive-related
osteonecrosis of the jaw in patients with lung and kidney cancers.
Int J Cancer. 2025;157:890-896. PubMedAbstract available
August 2025
ZHONG R, Chu T, Xiong L, Shi C, et al Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or
without chemotherapy in advanced NSCLC: A phase II study.
Int J Cancer. 2025;157:549-558. PubMedAbstract available
July 2025
DENG Y, Guo C, Zhang T, Chen Y, et al Comprehensive analysis of a real-world cohort identifies geranylgeranyl
diphosphate synthase 1 as a predictor of chemoresistance in small cell lung
cancer.
Int J Cancer. 2025 Jul 4. doi: 10.1002/ijc.70036. PubMedAbstract available
June 2025
WANG K, Xiang J, Zhou J, Chen C, et al Development and validation of a transcription factor regulatory network-based
signature for individualized prognostic risk in lung adenocarcinoma.
Int J Cancer. 2025;156:2440-2451. PubMedAbstract available
CHANG GC, Kapoor A, Lee CK, Su C, et al Optimizing management of stage IV EGFR mutant non-small cell lung cancer in Asia:
An expert opinion.
Int J Cancer. 2025 Jun 14. doi: 10.1002/ijc.35512. PubMedAbstract available
ZHAO R, Lu H, Yuan H, Chen S, et al Plasma proteomic profiles for early detection and risk stratification of
non-small cell lung carcinoma: A prospective cohort study with 52,913
participants.
Int J Cancer. 2025 Jun 6. doi: 10.1002/ijc.35518. PubMedAbstract available
April 2025
XIE Y, Fang H, Cheng W, Xu T, et al Furmonertinib in uncommon EGFR-mutated non-small cell lung cancer with central
nervous system metastases: A retrospective cohort study.
Int J Cancer. 2025 Apr 29. doi: 10.1002/ijc.35460. PubMedAbstract available
TSURUDA KM, Hektoen HH, Aamelfot C, Andreassen BK, et al Let's talk about sex: Survival among females and males in a real-world cohort
treated with pembrolizumab for non-small cell lung cancer.
Int J Cancer. 2025 Apr 29. doi: 10.1002/ijc.35445. PubMedAbstract available
NOFAL S, J Ostrin E, Zhang J, Wu J, et al Risk of second primary lung cancer among cancer survivors stratified by the site
of first primary cancer and the lung cancer screening eligibility status.
Int J Cancer. 2025 Apr 18. doi: 10.1002/ijc.35452. PubMedAbstract available
DIAO M, Wang Y, Wu S, He S, et al Estrogen, estrogen receptor and the tumor microenvironment of NSCLC.
Int J Cancer. 2025;156:1501-1508. PubMedAbstract available
NOMURA K, Takada K, Kinoshita F, Muto S, et al Prognostic impact of PD-L1 expression in surgically resected EGFR-mutant lung
adenocarcinoma: A real-world database study in Japan (CReGYT-01 EGFR study).
Int J Cancer. 2025;156:1480-1491. PubMedAbstract available
March 2025
HEMMINKI K, Zitricky F, Sundquist K, Sundquist J, et al Sex specific familial risk in lung cancer through changing histologies in Sweden.
Int J Cancer. 2025 Mar 29. doi: 10.1002/ijc.35431. PubMedAbstract available
February 2025
XU H, Fu X, Wang S, Ge Y, et al Immunoglobulin-like transcript 5 polarizes M2-like tumor-associated macrophages
for immunosuppression in non-small cell lung cancer.
Int J Cancer. 2025 Feb 5. doi: 10.1002/ijc.35360. PubMedAbstract available
January 2025
NALWOGA A, Jackson C, Fiorillo S, Manyeruke F, et al Evaluation of plasma alpha-1-antichymotrypsin as a marker for pulmonary Kaposi
sarcoma.
Int J Cancer. 2025 Jan 30. doi: 10.1002/ijc.35351. PubMedAbstract available
KANZAKI R, Reid S, Bolivar P, Sjolund J, et al FHL2 expression by cancer-associated fibroblasts promotes metastasis and
angiogenesis in lung adenocarcinoma.
Int J Cancer. 2025;156:431-446. PubMedAbstract available
LAZZARI N, Rigotto G, Montini B, Del Bianco P, et al Stemness and hybrid epithelial-mesenchymal profiles guide peritoneal
dissemination of malignant mesothelioma and pseudomyxoma peritonei.
Int J Cancer. 2025;156:201-215. PubMedAbstract available
December 2024
CHEI CL, Nakamura S, Watanabe K, Mizutani T, et al Assessing the performance of chest x-ray screening in detecting early-stage lung
cancer in the general population.
Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35316. PubMedAbstract available
LU G, Liu H, Wang H, Luo S, et al Genetic variants of FER and SULF1 in the fibroblast-related genes are associated
with non-small-cell lung cancer survival.
Int J Cancer. 2024 Dec 20. doi: 10.1002/ijc.35305. PubMedAbstract available
YANG ZM, Qin XY, Lu YY, Yao LK, et al Pathogen spectrum and clinical characteristics of lung cancer patients: A 10-year
retrospective study.
Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35272. PubMedAbstract available
BRANCO H, Rodrigues CA, Oliveira J, Mendes N, et al Preclinical studies on the antitumor and non-toxic effect of combining
pirfenidone with vinorelbine and carboplatin in non-small cell lung cancer.
Int J Cancer. 2024 Dec 4. doi: 10.1002/ijc.35276. PubMedAbstract available
November 2024
BURUS T, Patel MI, Christian WJ, Huang B, et al Sex-based differences in histologic lung cancer incidence trends in the United
States, 2005-2019.
Int J Cancer. 2024 Nov 21. doi: 10.1002/ijc.35268. PubMedAbstract available
JIANG C, Freedman RA, Punglia RS, Jemal A, et al Associations of radiotherapy receipt with lung cancer risk by histological
subtype among breast cancer survivors in the United States.
Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35257. PubMedAbstract available
TAKADA K, Takamori S, Shimokawa M, Pinato DJ, et al Prior antibiotics, proton pump inhibitors, and probiotics in patients with
extensive stage small cell lung cancer treated with immune checkpoint blockade: A
post-hoc analysis of the phase I/III IMpower 133 trial.
Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35249. PubMedAbstract available
October 2024
JEMAL A, Schafer EJ, Star J, Bandi P, et al Lung cancer incidence rates in young women and men by state in the United States.
Int J Cancer. 2024 Oct 11. doi: 10.1002/ijc.35188. PubMedAbstract available
MA Z, Zhu Z, Pang G, Gong F, et al Development and validation of a lung cancer polygenic risk score incorporating
susceptibility variants for risk factors.
Int J Cancer. 2024 Oct 8. doi: 10.1002/ijc.35210. PubMedAbstract available
KISHIDA R, Yin X, Abe SK, Rahman MS, et al Association between family history with lung cancer incidence and mortality risk
in the Asia Cohort Consortium.
Int J Cancer. 2024 Oct 3. doi: 10.1002/ijc.35191. PubMedAbstract available
September 2024
HU H, Zhu Q, Tang H, Zhang SC, et al The risk of treatment-related toxicities with PD-1/PD-L1 inhibitors in patients
with lung cancer.
Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35195. PubMedAbstract available
WANG H, Liu H, Tang X, Lu G, et al Potentially functional variants of PARK7 and DDR2 in ferroptosis-related genes
predict survival of non-small cell lung cancer patients.
Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35197. PubMedAbstract available
WIESWEG M, Kuter C, Schnorbach J, Keyl J, et al Oligometastatic non-small cell lung cancer: Impact of local and contemporary
systemic treatment approaches on clinical outcome.
Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35199. PubMedAbstract available
August 2024
SCHULTE C, Gauler T, Pottgen C, Friedel G, et al Survivorship program including long-term toxicities and quality-of-life
development over 10 years in a randomized trial in operable stage III
non-small-cell lung cancer (ESPATUE).
Int J Cancer. 2024 Aug 28. doi: 10.1002/ijc.35131. PubMedAbstract available
CHEN S, Cheng S, Cai J, Liu Z, et al The current therapeutic cancer vaccines landscape in non-small cell lung cancer.
Int J Cancer. 2024 Aug 7. doi: 10.1002/ijc.35088. PubMedAbstract available
July 2024
PULAWSKA-MOON K, Ponikwicka-Tyszko D, Lebiedzinska W, Pilaszewicz-Puza A, et al Novel ectopic expression of zona pellucida 3 glycoprotein in lung cancer promotes
tumor growth.
Int J Cancer. 2024 Jul 22. doi: 10.1002/ijc.35098. PubMedAbstract available
BRATIVNYK A, Ankill J, Helland A, Fleischer T, et al Multi-omics analysis reveals epigenetically regulated processes and patient
classification in lung adenocarcinoma.
Int J Cancer. 2024;155:282-297. PubMedAbstract available
YIN M, Liu L, Yan Y, Wang H, et al A targeting nanoplatform for chemo-photothermal synergistic therapy of small-cell
lung cancer.
Int J Cancer. 2024 Jul 10. doi: 10.1002/ijc.35065. PubMedAbstract available
ZHANG Q, Chen K, Yu X, Fan Y, et al Spotlight on the treatment of non-small cell lung cancer with rare genetic
alterations and brain metastasis: Current status and future perspectives.
Int J Cancer. 2024 Jul 3. doi: 10.1002/ijc.35070. PubMedAbstract available
June 2024
MELOSKY B, Vincent MD, McGuire AL, Brade AM, et al Modern era systemic therapies: Expanding concepts of cure in early and locally
advanced non-small cell lung cancer.
Int J Cancer. 2024 Jun 20. doi: 10.1002/ijc.35031. PubMedAbstract available
ZHANG B, Li C, Wu J, Zhang J, et al DeepCG: A cell graph model for predicting prognosis in lung adenocarcinoma.
Int J Cancer. 2024;154:2151-2161. PubMedAbstract available
CHEN C, Zhou X, Gao X, Pan R, et al Immune responses and reinfection of SARS-CoV-2 Omicron variant in patients with
lung cancer.
Int J Cancer. 2024 Jun 5. doi: 10.1002/ijc.35038. PubMedAbstract available
GU Z, Huang P, Zhao J, Luo C, et al Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR
mutations was associated with a favorable prognosis to EGFR-TKIs.
Int J Cancer. 2024;154:1979-1986. PubMedAbstract available
SEBASTIAN M, Eberhardt WEE, von der Heyde E, Dorfel S, et al Patient-reported outcomes in advanced NSCLC before and during the COVID-19
pandemic: Real-world data from the German prospective CRISP Registry
(AIO-TRK-0315).
Int J Cancer. 2024;154:1967-1978. PubMedAbstract available
May 2024
MIYAMORI D, Kamitani T, Yoshida S, Kikuchi Y, et al Effects of the Coronavirus disease 2019 pandemic on mortality in patients with
lung cancer: A multiple mediation analysis in Japan.
Int J Cancer. 2024 May 24. doi: 10.1002/ijc.35042. PubMedAbstract available
WANG Z, Zhang Q, Wang C, Herth FJF, et al Multiple primary lung cancer: Updates and perspectives.
Int J Cancer. 2024 May 23. doi: 10.1002/ijc.34994. PubMedAbstract available
KOURO T, Higashijima N, Horaguchi S, Mano Y, et al Novel chimeric antigen receptor-expressing T cells targeting the malignant
mesothelioma-specific antigen sialylated HEG1.
Int J Cancer. 2024;154:1828-1841. PubMedAbstract available
April 2024
RAHMAN ML, Shu XO, Jones DP, Hu W, et al A nested case-control study of untargeted plasma metabolomics and lung cancer
among never-smoking women within the prospective Shanghai Women's Health Study.
Int J Cancer. 2024 Apr 23. doi: 10.1002/ijc.34929. PubMedAbstract available
MULSHINE JL, Avila RS, Rizzo AA, Estepar RSJ, et al Quantitative imaging workshop XIX: Utilizing quantitative thoracic imaging to
optimize population health final summary.
Int J Cancer. 2024;154:1365-1370. PubMedAbstract available
March 2024
LIU X, Xie X, Sui C, Liu X, et al Unraveling the cross-talk between N6-methyladenosine modification and non-coding
RNAs in breast cancer: Mechanisms and clinical implications.
Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34900. PubMedAbstract available
February 2024
YIN X, Kishida R, Abe SK, Islam MR, et al Association between reproductive factors with lung cancer incidence and
mortality: A pooled analysis of over 308,000 females in the Asia cohort
consortium.
Int J Cancer. 2024 Feb 20. doi: 10.1002/ijc.34866. PubMedAbstract available
WELSCH E, Holzer B, Schuster E, Fabikan H, et al Prognostic significance of circulating tumor cells and tumor related transcripts
in small cell lung cancer: A step further to clinical implementation.
Int J Cancer. 2024 Feb 14. doi: 10.1002/ijc.34886. PubMedAbstract available
January 2024
MORITA A, Ichihara E, Inoue K, Fujiwara K, et al Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or
without chemotherapy for patients with advanced non-small-cell lung cancer.
Int J Cancer. 2024 Jan 9. doi: 10.1002/ijc.34842. PubMedAbstract available
ZAHED H, Feng X, Sheikh M, Bray F, et al Age at diagnosis for lung, colon, breast and prostate cancers: An international
comparative study.
Int J Cancer. 2024;154:28-40. PubMedAbstract available
KEMMOTSU N, Ninomiya K, Kunimasa K, Ishino T, et al Low frequency of intracranial progression in advanced NSCLC patients treated with
cancer immunotherapies.
Int J Cancer. 2024;154:169-179. PubMedAbstract available
December 2023
MORISUE R, Kojima M, Suzuki T, Watanabe R, et al Common clinicopathological and immunological features of sarcomatoid carcinoma
across organs: A histomorphology-based cross-organ study.
Int J Cancer. 2023;153:1997-2010. PubMedAbstract available
November 2023
JANSEN L, Schwettmann L, Behr C, Eberle A, et al Trends in cancer incidence by socioeconomic deprivation in Germany in 2007 to
2018: An ecological registry-based study.
Int J Cancer. 2023;153:1784-1796. PubMedAbstract available
PELOS G, Riester M, Pal J, Myacheva K, et al Fast proliferating and slowly migrating non-small cell lung cancer cells are
vulnerable to decitabine and retinoic acid combinatorial treatment.
Int J Cancer. 2023 Nov 10. doi: 10.1002/ijc.34783. PubMedAbstract available
October 2023
YU Z, Dong X, Song M, Xu A, et al Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing
CDC73 and p53 mediated apoptosis.
Int J Cancer. 2023 Oct 19. doi: 10.1002/ijc.34769. PubMedAbstract available
WEI X, Sun D, Gao J, Zhang J, et al Development and evaluation of a polygenic risk score for lung cancer in
never-smoking women: A large-scale prospective Chinese cohort study.
Int J Cancer. 2023 Oct 17. doi: 10.1002/ijc.34765. PubMedAbstract available
VAN VEELEN A, Veerman GDM, Verschueren MV, Gulikers JL, et al Exploring the impact of patient-specific clinical features on osimertinib
effectiveness in a real-world cohort of patients with EGFR mutated non-small cell
lung cancer.
Int J Cancer. 2023 Oct 15. doi: 10.1002/ijc.34742. PubMedAbstract available
YU Z, Ni P, Yu H, Zuo T, et al Effectiveness of a single low-dose computed tomography screening for lung cancer:
A population-based perspective cohort study in China.
Int J Cancer. 2023 Oct 11. doi: 10.1002/ijc.34741. PubMedAbstract available
TOMONAGA Y, de Nijs K, Bucher HC, de Koning H, et al Cost-effectiveness of risk-based low-dose computed tomography screening for lung
cancer in Switzerland.
Int J Cancer. 2023 Oct 4. doi: 10.1002/ijc.34746. PubMedAbstract available
September 2023
SJODAHL G, Eriksson P, Holmsten K, Abrahamsson J, et al Metastasis and recurrence patterns in the molecular subtypes of urothelial
bladder cancer.
Int J Cancer. 2023 Sep 6. doi: 10.1002/ijc.34715. PubMedAbstract available